• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

COURAGE Trial: Optimal Medical Therapy Alone is Sufficient for Patients with Stable Angina: Adding PCI Does Not Help – ILLUSTRATE Study Shows Torcetrapib Raises HDL But Fails to Lower Coronary Risk

  • — 26 Mar, 2007
AudioMedica News
AudioMedica News
COURAGE Trial: Optimal Medical Therapy Alone is Sufficient for Patients with Stable Angina: Adding PCI Does Not Help - ILLUSTRATE Study Shows Torcetrapib Raises HDL But Fails to Lower Coronary Risk
COURAGE Trial: Optimal Medical Therapy Alone is Sufficient for Patients with Stable Angina: Adding PCI Does Not Help - ILLUSTRATE Study Shows Torcetrapib Raises HDL But Fails to Lower Coronary Risk
00:00 /
RSS Feed
Share
Link
Embed
Steven Nissen

STEVEN NISSEN, Cleveland Clinic, OH

REFERENCE: N Engl J Med 2007 356
Reporting from: American College of Cardiolgy New Orleans

Two big studies published in the New England Journal of Medicine and presented simultaneously at the American College of Cardiology meeting in New Orleans have shown that two emerging therapies aimed at reducing risks in patients with coronary disease have failed to do so. The president of the ACC, Steven Nissen, talked with Peter Goodwin about the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial, in which patients with stable coronary artery disease were randomized to receive optimal medical therapy with or without PCI. He also discussed findings of the ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) study in which the cholesteryl ester transfer protein inhibitor, torcetrapib was found to have adverse effects when used for modifying lipid profiles among coronary patients.

[audio:https://www.audiomedica.com/podcasting/cardio/acc2007/070327_steven_nissen.mp3]

You may also like...

  • Increased Use of Recommended Drugs Explains Improved Trends in Prognosis after Myocardial Infarction Increased Use of Recommended Drugs Explains Improved Trends in Prognosis after Myocardial Infarction 26 Mar, 2007
  • Valentin Fuster CABG better than pci in patients with diabetes and multi-vessel coronary disease 10 Nov, 2012
  • Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006 Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006 18 Nov, 2006
  • Czech Republic Sees Massive Decline In Cardiovascular Deaths With Hypertension Treatment And Awareness Czech Republic Sees Massive Decline In Cardiovascular Deaths With Hypertension Treatment And Awareness 18 Jun, 2009

1 Comment

  1. Prof.Abdul Maguid Al Ballat says:
    May 21, 2007 at 6:32 am

    Type your comment here.

  • Previous story Bioabsorbable Everolimus-Eluting Stent: 6-Month Angiographic and IVUS Results
  • Next story “ERASE” Trial: Infusions of Reconstituted HDL Treat Atherosclerosis in Patients with Acute Coronary Syndromes
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Microbiome Diversity Key To Survival After Allogeneic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • New Front Line Standard for Older Patients with Chronic…
    • CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second…
  • Home
  • Cardiovascular
  • COURAGE Trial: Optimal Medical Therapy Alone is Sufficient for Patients with Stable Angina: Adding PCI Does Not Help – ILLUSTRATE Study Shows Torcetrapib Raises HDL But Fails to Lower Coronary Risk

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.